SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: MediPoint: Companion Diagnostic Tests in Oncology Report 2014 - US Analysis and Market Forecasts

[May 26, 2014]

Research and Markets: MediPoint: Companion Diagnostic Tests in Oncology Report 2014 - US Analysis and Market Forecasts

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/9g79jd/medipoint) has announced the addition of the "MediPoint: Companion Diagnostic Tests in Oncology - US Analysis and Market Forecasts" report to their offering.

A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked to a disease condition or therapy. This report provides an analysis of the companion diagnostic market for four major cancers in the US, the 5EU (France, Germany, Italy, Spain, and UK), Brazil, and the some of the Asia-Pacific (APAC) regions (Japan, China, and India), and identifies the unmet needs in this companion diagnostics market. This report analyses companion diagnostic tests used in breast, colorectal, melanoma and non-small cell lung cancer. This report also discusses physician attitudes towards current companion diagnostic tests, and the future of companion diagnostic tests. This report focuses on the major test kits that are supplied to pathology laboratories.

The major feature of the companion diagnostic testing market is the current domination of tests for mutations important in the prognosis and diagnosis of non-small cell lung cancer (NSCLC), with the two market leaders being Roche and Qiagen. According to Our forecast, in 2014, NSCLC companion diagnostic tests account for 67% of the US market by value. While more human epidermal growth factor receptor 2 (HER2) tests are carried out, because the NSCLC tests have been principally more expensive molecular tests rather than the cheaper immunohistochemistry (IHC) test that typifies HER2 testing, the value of the NSCLC market is considerably higher.


Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Industry Overview

  • Emergence of Companion Diagnostics
  • Disease Applications
  • Companion Diagnostics Technologies
  • Companion Diagnostics Development
  • Clinical Outcomes
  • Testing Trends
  • Market Access
  • Regulatory Issues and Recalls
  • Reimbursement of Companion Diagnostic Tests
  • Economic Impact
  • Market Drivers
  • Market Barriers

4 Competitive Assessment

  • Immunohistochemistry
  • Fluorescence In Situ Hybridization
  • Polymerase Chain Reaction
  • Breast Cancer Companion Diagnostic Tests
  • Colorectal Cancer Companion Diagnostic Tests
  • Melanoma Companion Diagnostic Tests
  • Non-Small Cell Lung Cancer Companion Diagnostic Tests

5 Unmet Needs

  • Need for Improved Cancer Treatments
  • Need for Objective Tests
  • Need for High-Throughput Tests
  • Certainty of Reimbursement
  • Amount and Type of Tissue Needed for Test
  • Who Should be Tested?
  • Test Accuracy
  • Increasing Test Complexity and Increased Process Failure

6 Pipeline Products

  • Breast Cancer Companion Diagnostic Tests
  • Colorectal Cancer Companion Diagnostic Tests
  • Melanoma Companion Diagnostic Tests
  • Non-Small Cell Lung Cancer Companion Diagnostic Tests

7 Clinical Trials to Watch

  • Key Clinical Trials Utilizing Pipeline Companion Diagnostic Tests Linked to Specific Drug Therapies

8 Current and Future Players

  • Companion Diagnostics Business Models
  • Pharmaceutical/Therapy Companies Developing Companion Diagnostic Tests
  • Diagnostics Companies Developing Companion Diagnostic Tests (in Partnership with Pharmaceutical Companies)

9 Market Outlooks

  • Breast Cancer Companion Diagnostic Tests
  • Colorectal Cancer Companion Diagnostic Tests
  • Melanoma Companion Diagnostic Tests
  • Non-Small Cell Lung Cancer Companion Diagnostic Tests
  • Technique

10 Appendix

Companies Mentioned

  • Amgen
  • Arno Therapeutics
  • AstraZeneca
  • Bristol-Myers Squibb
  • Clovis Oncology
  • Eli Lilly and Company
  • Genentech (Roche)
  • Pfizer
  • Syndax Pharmaceuticals
  • Abbott Laboratories
  • Amoy Diagnostics (Amoy Diagnostics)
  • Biogenex Laboratories
  • BioMérieux
  • Dako (Agilent (News - Alert) Technologies)
  • Illumina
  • Leica Biosystems
  • Life Technologies (Thermo Fisher Scientific)
  • MolecularMD
  • Myriad Genetics
  • Qiagen
  • Roche Diagnostics
  • Siemens (News - Alert) Healthcare
  • Ventana Medical Systems

For more information visit http://www.researchandmarkets.com/research/9g79jd/medipoint


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy